BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions

BridgeBio Pharma will present long-term efficacy and safety data from its Phase 3 ATTRibute-CM trial at the American College of Cardiology Annual Scientific Sessions. The data will be shared in a late-breaking oral presentation and three posters. Acoramidis, a transthyretin stabilizer, is indicated for the treatment of transthyretin-mediated amyloidosis cardiomyopathy in adults to reduce cardiovascular death and hospitalization. Adverse reactions reported in patients treated with Attruby include diarrhea and upper abdominal pain.